Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development

About this update from Helix Biopharma Corp.

Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development (TheNewswire)   Vancouver, British Columbia – TheNewswire - June 30, 2026 – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, today announced the appointments of Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations. The appointments further strengthen Helix’s executive leadership team as the Company prepares for its planned U.S. securities exchange listing, advances the next stage of development for L-DOS47 through LDOS007, the Company’s planned Phase IB/Randomized Phase II study in first-line non-small cell lung cancer (NSCLC), and continues building the legal, governance and operational infrastructure required to support its next phase of growth.   “The next stage of Helix’s evolution demands a different kind of company than the one we were building two years ago,” said Thomas Mehrling, MD, PhD, Chief Executive Officer of the Company. “As we prepare for our planned U.S. securities exchange listing and advance L-DOS47 into its next stage of clinical development, we are deliberately strengthening every part of the organization. From our legal and governance framework to our clinical execution capabilities, we are building the leadership team required to support the next phase of Helix’s growth.”   “With the preparation of our base shelf prospectus underway and the auditor review of our second-quarter financials completed, we are executing on a clear capital markets roadmap as we prepare for our planned U.S. securities exchange listing. Helen and David are exceptional additions to Helix. Helen brings decades of experience navigating the legal and governance challenges faced by growing life sciences companies, while David has successfully led complex global oncology programs from planning through execution. Together, they significantly strengthen our ability to deliver on our clinical, corporate and capital markets objectives.”   Helen Middleton, BPharm, LPC, ...

View stock analysis, news, and events for Helix Biopharma Corp.